Ischemic stroke
Conditions
Interventions
Healthy Control Group:None
Case Group:None
Case Control Group:None
Sponsors
The Second Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the case group: The subject has signed the informed consent form. 2. Meet the diagnostic criteria for acute cerebral infarction as stipulated in the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2023)". 3. Acute cerebral infarction occurred in the internal carotid artery system (anterior circulation), with an onset time of less than 4.5 hours. 4.18 years old = 80 years old. 5. Received intravenous thrombolysis but no mechanical thrombectomy. 6. First-onset cerebral infarction or a history of previous cerebral infarction without remaining neurological deficits. Inclusion criteria for the case control group: The subject has signed the informed consent form. 2. Meet the diagnostic criteria for acute cerebral infarction as stipulated in the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2023)". 3. Acute cerebral infarction occurred in the internal carotid artery system (anterior circulation), with an onset time of less than 4.5 hours. 4.18 years old = 80 years old. 5. No intravenous thrombolysis or mechanical thrombectomy was performed. 6. First-onset cerebral infarction or a history of previous cerebral infarction without remaining neurological deficits. Inclusion criteria for the healthy control group: The subject has signed the informed consent form. 2.18 years old <= age <=80 years old. 3. Blood routine test: Red blood cell count, MCHC, hemoglobin, white blood cell count, lymphocyte count, neutrophil count and monocyte count are all within the normal range. 4.TG, TC, HDL-C, LDL-C, blood glucose and glycated hemoglobin are within the normal range.
Exclusion criteria
Exclusion criteria: Exclusion criteria for the case group Head CT or MRI examination shows intracranial hemorrhagic diseases (such as hemorrhagic stroke, subarachnoid hemorrhage, intracranial hematoma, epidural hematoma). 2. There were previous symptoms of neurological deficits, and the modified Rankin score (mRS) was >=2 points. 3. Patients with severe functional disorders of vital organs such as the heart, liver and kidneys. 4. Patients with malignant tumors, hematological diseases, immune system diseases, tuberculosis or moderate to severe infections. 5. There is a history of blood transfusion, surgery or trauma in the past. 6. Patients with abnormal electrocardiograms. 7. Pregnant or lactating women. 8.During this study period, the patient has been enrolled or is planned to be enrolled in another clinical drug or device/intervention study. Exclusion criteria for the case control group: Head CT or MRI examination shows intracranial hemorrhagic diseases (such as hemorrhagic stroke, subarachnoid hemorrhage, intracranial hematoma, epidural hematoma). 2. There were previous symptoms of neurological deficits, and the modified Rankin score (mRS) was >=2 points. 3. Patients with severe functional disorders of vital organs such as the heart, liver and kidneys. 4. Patients with malignant tumors, hematological diseases, immune system diseases, tuberculosis or moderate to severe infections. 5. There is a history of blood transfusion, surgery or trauma in the past. 6. Patients with abnormal electrocardiograms. 7. Patients undergoing intravenous thrombolysis and endovascular interventional therapy. 8. Pregnant or lactating women. 9.During this study period, the patient has been enrolled or is planned to be enrolled in another clinical drug or device/intervention study. Exclusion criteria for the healthy control group: 1. Other diseases exist: neurological diseases (cerebral infarction, cerebral hemorrhage, multiple sclerosis, etc.); All kinds of acute and chronic digestive system diseases; Circulatory system diseases (coronary heart disease, heart failure, atrial fibrillation); Respiratory system diseases (chronic obstructive pulmonary disease, chronic bronchitis, asthma); Metabolic diseases (obesity, hyperlipidemia, diabetes, metabolic syndrome, osteoporosis); Urinary system diseases (chronic kidney disease, renal failure, kidney stones); Blood system diseases (anemia); Immune system diseases and others (severe infections, gout, depression, mental illness, chronic fatigue syndrome, fibromyalgia, food allergies, tumors, etc.). 2. There is a history of blood transfusion, surgery and trauma in the past. 3. Abnormal electrocardiogram. 4. Pregnant or lactating women. 5.During this study period, the subjects have been enrolled or are planned to be enrolled in another clinical drug or device/intervention study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Regulatory T cell;High Mobility Group Box 1;Matrix metallopeptidase 9;Transforming growth factor-ß;Interleukin 10; | — |
Countries
China
Contacts
Public ContactXiangjian Zhang
The Second Hospital of Hebei Medical University
Outcome results
None listed